Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(1.86)
# 2,968
Out of 4,784 analysts
47
Total ratings
26.09%
Success rate
-2.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $3.65 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $11.58 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.47 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $11.93 | - | 1 | Dec 9, 2024 | |
| ALEC Alector | Reiterates: Overweight | n/a | $1.29 | - | 5 | Nov 26, 2024 | |
| ANNX Annexon | Reiterates: Overweight | n/a | $2.25 | - | 9 | Nov 15, 2024 | |
| VSTM Verastem | Reiterates: Overweight | n/a | $6.19 | - | 1 | Oct 18, 2024 | |
| VERA Vera Therapeutics | Reiterates: Overweight | $107 | $26.63 | +301.80% | 7 | Oct 3, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Overweight | n/a | $19.99 | - | 1 | Jun 27, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Overweight | n/a | $4.46 | - | 4 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.93 | +70.65% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.19 | +992.44% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $6.99 | +14.45% | 1 | Mar 20, 2023 |
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.65
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $11.58
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.47
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.93
Upside: -
Alector
Nov 26, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.29
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.25
Upside: -
Verastem
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.19
Upside: -
Vera Therapeutics
Oct 3, 2024
Reiterates: Overweight
Price Target: $107
Current: $26.63
Upside: +301.80%
Dianthus Therapeutics
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $19.99
Upside: -
Jasper Therapeutics
Jun 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.46
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.93
Upside: +70.65%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $1.19
Upside: +992.44%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $6.99
Upside: +14.45%